Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $1.56 million for the quarter.
Armata Pharmaceuticals Stock Up 1.1 %
Armata Pharmaceuticals stock opened at $1.89 on Thursday. The company has a market capitalization of $68.38 million, a PE ratio of -1.15 and a beta of 0.87. Armata Pharmaceuticals has a twelve month low of $1.80 and a twelve month high of $4.25.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
See Also
- Five stocks we like better than Armata Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- High Dividend REITs: Are They an Ideal Way to Diversify?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How to Find Undervalued Stocks
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
